Literature DB >> 17708127

Modafinil in the treatment of excessive daytime sleepiness.

Roxanne M Valentino1, Nancy Foldvary-Schaefer.   

Abstract

Modafinil (Provigil) is approved for treating excessive daytime sleepiness associated with narcolepsy, for shift-work sleep disorder, and as an adjunctive treatment in patients with obstructive sleep apnea syndrome who have residual daytime sleepiness despite optimal treatment with continuous positive airway pressure. Although modafinil improves measures of sleepiness, it does not generally normalize them, and it may be less effective than other stimulants for some narcoleptic patients. We need head-to-head comparisons of modafinil with traditional stimulants in humans to better define its role. We review the current approved and off-label uses of this drug and the evidence behind them.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17708127     DOI: 10.3949/ccjm.74.8.561

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  6 in total

Review 1.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

2.  Modafinil-Induced Psychosis: A Case Report.

Authors:  Özgür Aytaş; Hayriye Dilek Yalvaç
Journal:  Noro Psikiyatr Ars       Date:  2015-03-01       Impact factor: 1.339

3.  A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.

Authors:  Laura Christina Wittkampf; Johannes Arends; Leo Timmerman; Marike Lancel
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

4.  Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial.

Authors:  Oliver Freudenreich; David C Henderson; Eric A Macklin; A Eden Evins; Xiaoduo Fan; Cori Cather; Jared P Walsh; Donald C Goff
Journal:  J Clin Psychiatry       Date:  2009-08-11       Impact factor: 4.384

5.  A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

Authors:  David H Winslow; Charles H Bowden; Karen P DiDonato; Pamela A McCullough
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

6.  High resolution mapping of modafinil induced changes in glutamate level in rat brain.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Kavindra Nath; Gaurav Verma; Ravi Prakash Reddy Nanga; Hari Hariharan; John A Detre; Neill Epperson; Ravinder Reddy
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.